The Latest Cardiac and Vascular News
PONTE VEDRA, Fla., Feb. 1, 2023 /PRNewswire/ — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, announced today the formation of its Scientific Advisory Board (SAB) in support of the development of tecarfarin for the prevention of systemic thromboembolism, […]
SCHAFFHAUSEN, SWITZERLAND / ACCESSWIRE / February 1, 2023 / Occlutech Holding AG Occlutech Holding AG (“Occlutech”), one of the world’s leading providers of minimally invasive structural heart disease devices, appoints Dr. Morwan Choli as the new Vice President of Regulatory Affairs & Quality (VP RA&Q). Morwan Choli will be part of […]
DUBLIN, Ohio, Jan. 31, 2023 /PRNewswire/ — Sarnova, a leading specialty distributor of healthcare products and services, announced today that Brian LaDuke, currently, President of Sarnova’s Cardiac Response division, has been appointed as the next Chief Executive Officer (CEO) of Sarnova, effective March 1, 2023. Current Sarnova CEO, Jeff Prestel, will transition to a position […]
AMGEN ALSO PROVIDES 2023 GUIDANCE EXCLUDING ANY CONTRIBUTION FROM THE ANNOUNCED ACQUISITION OF HORIZON THERAPEUTICS THOUSAND OAKS, Calif., Jan. 31, 2023 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year 2022 versus comparable periods in 2021. “We executed effectively in 2022, delivering strong volume growth, advancing numerous […]
Cumulative CytoSorb treatments surpassed 195,000. Q4 2022 product sales rebounded from Q3 2022 low. Adjusted for constant currency, Core non-COVID 2022 product sales were within 5% of that achieved in 2021 and greater than 30% increased from pre-pandemic 2019 PRINCETON, N.J., Jan. 31, 2023 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment […]
~ Preliminary fourth quarter 2022 sales increase of 18% to 19% versus 2021 ~ ~ Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call ~ PLANO, Texas, Jan. 30, 2023 (GLOBE NEWSWIRE) — Integer Holdings Corporation (NYSE: ITGR), a leading medical device outsource manufacturer, announces preliminary financial […]
Mesoblast Operational and Financial Highlights for Quarter Ended December 31, 2022 NEW YORK, Jan. 31, 2023 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the second quarter ended December 31, 2022. Financial Highlights Revenue from royalties […]
Urges Shareholders to Vote “AGAINST” Sarissa’s Proposals on the WHITE Proxy Card Highlights Significant Changes Implemented Over Last 18 Months – New Strategy, New Leadership Team and Significantly Refreshed Board; Transformation Underway with Strong Early Progress Advancing Geographic Expansion and Operational and Financial Excellence Underscores Sarissa’s Misguided Proxy Contest – […]
Fourth-quarter highlights Group sales amounted to EUR 5.4 billion, with 3% comparable sales growth driven by component supply improvements, while Philips’ supply chain conditions remain challenging Comparable order intake decreased 8%, due to lower demand for COVID-19-related products compared to 2021 and company actions to improve the order book margin […]
4Q Revenues up 8% year-over-year, Organic revenues* up 13% 4Q Net income of $554 million versus $564 million for the prior year, Adjusted EBIT* of $844 million versus $827 million 4Q EPS were $1.21 versus $1.24 in the prior year, Adjusted EPS* were $1.31 versus $1.36 Reaffirmed 2023 guidance disclosed […]
